Top Markets
Coin of the day
Palvella Therapeutics, Inc. Palvella Therapeutics, Inc.

Palvella Therapeutics, Inc.

PVLA
Clasificación en acciones #6151
Palvella Therapeutics, Inc. is a clinical-stage biopharmaceutical company... Palvella Therapeutics, Inc. is a clinical-stage biopharmaceutical company dedicated to the discovery, development, and commercialization of innovative treatments for patients afflicted with severe and uncommon inherited skin conditions. Central to its pipeline is QTORIN 3.9% rapamycin anhydrous gel (referred to as QTORIN rapamycin), which is currently undergoing Phase 3 clinical trials for microcystic lymphatic malformations. Additionally, this drug is in Phase 2 evaluation for treating cutaneous venous malformations. Beyond these specific indications, Palvella is also advancing QTORIN rapamycin for the treatment of other dermatological diseases driven by the mTOR pathway. The company's headquarters are situated in Wayne, Pennsylvania.
Precio por acción
$153.93
Capitalización bursátil
$2.21B
Cambio (1 día)
-0.26%
Cambio (1 año)
172.68%
País
US
Comercio Palvella Therapeutics, Inc. (PVLA)

Categoría

Historial de rendimiento por dividendo de Palvella Therapeutics, Inc. (PVLA)
Rendimiento por dividendo (TTM) de Palvella Therapeutics, Inc. (símbolo bursátil: PVLA) al 2026: 0
Rendimiento promedio por dividendo de los últimos 5 años: 0.00%
Historial de rendimiento por dividendo de Palvella Therapeutics, Inc. (PVLA) desde 2026 hasta 2026
Rendimiento por dividendo al final de cada año (TTM)
Año Rendimiento por dividendo Cambiar
Not enough data for the provided dates.
Rendimientos por dividendo (TTM) de empresas similares o competidoras
Empresa Rendimiento por dividendo País
0.00%
US
0.00%
NL
3.12%
AU
0.00%
US
0.00%
CH